ALX Oncology Holdings Inc.
ALXOHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Valued at $277.9M, ALXO is a micro-cap name in its sector. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Market Cap
$277.9M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-3.74
EPS (TTM)
$-1.15
EPS (Fwd)
$-0.54
ROE
-80.7%
ROA
-40.4%
Cash
$138.2M
Total Debt
$11.0M
Free CF
-$41.2M
52W Change
81.1%
Annual Financials
Cash vs Debt
Where ALXO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ALXO finished 6.12% above its 150-day moving average ($1.96) and 14.29% above its 200-day moving average ($1.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALXO overbought or oversold?
At the September 3, 2026 close, ALXO's RSI(14) was 60.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ALX Oncology Holdings Inc. holds $138.2M in cash against $11.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$41.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -80.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, ALX Oncology Holdings Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ALXO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.